Long-term consequences of childhood-onset congenital adrenal hyperplasia

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 16, Issue 2, 2002, Pages 273-288

  White, Perrin C ^a   Speiser, Phyllis W ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adrenal hyperplasia; Congenital (CAH); Steroid 21 hydroxylase deficiency (CAH 21OHD); Steroid 21 mono oxygenase deficiency

Indexed keywords

ALDOSTERONE; ANDROGEN; ANDROSTENEDIONE; ANTIANDROGEN; AROMATASE; AROMATASE INHIBITOR; CLOMIFENE CITRATE; CORTICOSTEROID; CORTICOTROPIN; DEXAMETHASONE; ENZYME; ESTROGEN; FLUDROCORTISONE; FLUTAMIDE; GLUCOCORTICOID; GONADORELIN DERIVATIVE; GROWTH HORMONE; HYDROCORTISONE; HYDROCORTISONE SODIUM SUCCINATE; HYDROXYPROGESTERONE; LONG ACTING DRUG; METHYLPREDNISOLONE SODIUM SUCCINATE; MINERALOCORTICOID; PREDNISONE; RENIN; STEROID; STEROID 21 MONOOXYGENASE; TESTOLACTONE; TESTOSTERONE; UNINDEXED DRUG; METHYLPREDNISOLONE; SEX HORMONE; SODIUM CHLORIDE; TETRACOSACTIDE;

ADOLESCENCE; ADRENAL INSUFFICIENCY; ADRENALECTOMY; ADULTHOOD; BIOCHEMISTRY; CHILD; CHILDHOOD; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEVELOPMENT; CONGENITAL ADRENAL HYPERPLASIA; CUSHING SYNDROME; DIAGNOSTIC VALUE; DOSE CALCULATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; ENZYME DEFICIENCY; FEMALE; GENETIC COUNSELING; GENOTYPE PHENOTYPE CORRELATION; GROWTH RETARDATION; HETEROZYGOTE; HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HORMONE SYNTHESIS; HUMAN; INFANCY; INFERTILITY; INHERITANCE; LOW DRUG DOSE; NEWBORN DISEASE; OUTCOMES RESEARCH; OVARY POLYCYSTIC DISEASE; PATHOPHYSIOLOGY; PREGNANCY; PSYCHOSEXUAL DEVELOPMENT; REVIEW; TESTIS TUMOR; GONAD FUNCTION; HEREDITY; HORMONAL THERAPY; IDIOPATHIC DISEASE; LONG TERM CARE; MALE INFERTILITY; ONSET AGE; POPULATION; PRECOCIOUS PUBERTY; PREGNANCY COMPLICATION; REPRODUCTION; SALT LOSING NEPHRITIS; STEROID 21 MONOOXYGENASE DEFICIENCY;

EID: 0036033695     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1053/beem.2002.0198     Document Type: Article

References (81)

1. Merke DP, Chrousos GP, Eisenhofer G et al. Adrenomedullary dysplasia and hypofunction in patients with classic 21-hydroxylase deficiency. New England Journal of Medicine 2000; 343: 1362-1368.
2. Wilson RC, Mercado AB, Cheng KC et al. Steroid 21-hydroxylase deficiency: genotype may not predict phenotype. Journal of Clinical Endocrinology and Metabolism 1995; 80: 2322-2329.
3. Thilen A, Woods KA, Perry LA et al. Early growth is not increased in untreated moderately severe 21-hydroxylase deficiency (see comments). Acta Paediatrica 1995; 84: 894-898.
4. Speiser PW, Dupont B, Rubinstein P et al. High frequency of nonclassical steroid 21-hydroxylase deficiency. American Journal of Human Genetics 1985; 37: 650-667.
5. Speiser PW, New MI & White PC. Molecular genetic analysis of nonclassic steroid 21-hydroxylase deficiency associated with HLA-B14, DR1. New England Journal of Medicine 1988; 319: 19-23.
6. Kohn B, Levine LS, Pollack MS et al. Late-onset steroid 21-hydroxylase deficiency: a variant of classical congenital adrenal hyperplasia. Journal of Clinical Endocrinology and Metabolism 1982; 55: 817-827.
7. Moran C, Azziz R, Carmina E et al. 21-Hydroxylase-deficient nonclassic adrenal hyperplasia is a progressive disorder: a multicenter study (in process citation). American Journal of Obstetrics and Gynecology 2000; 183: 1468-1474 [MEDLINE record in progress].
8. Eugster EA, Dimeglio LA, Wright JC et al. Height outcome in congenital adrenal hyperplasia caused by 21-hydroxylase deficiency: a meta-analysis. Journal of Pediatrics 2001; 138: 26-32.
9. Iluizenga NA, Koper JW, De Lange P et al. A polymorphism in the glucocorticoid receptor gene may be associated with an increased sensitivity to glucocorticoids in vivo. Journal of Clinical Endocrinology Metabolism 1998; 83: 144-151.
10. Merke DP, Keil MF, Jones JV et al. Flutamide, testolactone, and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia. Journal of Clinical Endocrinology and Metabolism 2000; 85: 1114-1120.
11. Quintos JB, Vogiatzi MG, Harbison MD et al. Growth hormone therapy alone or in combination with gonadotropin-releasing hormone analog therapy to improve the height deficit in children with congenital adrenal hyperplasia. Journal of Clinical Endocrinology and Metabolism 2001; 86: 1511-1517.
12. New MI, Gertner JM, Speiser PW et al. Growth and final height in classical and nonclassical 21-hydroxylase deficiency. Acta Paediatrica Japonica 1988; 30 (supplement): 79-88.
13. Cameron FJ, Tebbutt N, Montalto J et al. Endocrinology and auxology of sibships with non-classical congenital adrenal hyperplasia. Archives of Disease in Childhood 1996; 74: 406-411.
14. Helleday J, Siwers B, Ritzen EM et al. Subnormal androgen and elevated progesterone levels in women treated for congenital virilizing 21-hydroxylase deficiency. Journal of Clinical Endocrinology and Metabolism 1993; 76: 933-936.
15. Speiser PW, Serrat J, New MI et al. Insulin insensitivity in adrenal hyperplasia due to nonclassical steroid 21-hydroxylase deficiency. Journal of Clinical Endocrinology and Metabolism 1992; 75: 1421-1424.
16. Mather KJ, Kwan F & Corenblum B. Hyperinsulinemia in polycystic ovary syndrome correlates with increased cardiovascular risk independent of obesity. Fertility and Sterility 2000; 73: 150-156.
17. Ibanez L, Potau N, Chacon P et al. Hyperinsulinaemia, dyslipaemia and cardiovascular risk in girls with a history of premature pubarche. Diabetologia 1998; 41: 1057-1063.
18. Bonaccorsi AC, Adler I & Figueiredo JG. Male infertility due to congenital adrenal hyperplasia: testicular biopsy findings, hormonal evaluation, and therapeutic results in three patients. Fertility and Sterility 1987; 47: 664-670.
19. Barnes RB, Rosenfield RL, Ehrmann DA et al. Ovarian hyperandrogynism as a result of congenital adrenal virilizing disorders: evidence for perinatal masculinization of neuroendocrine function in women. Journal of Clinical Endocrinology and Metabolism 1994; 79: 1328-1333.
20. Holmes-Walker DJ, Conway GS, Honour JW et al. Menstrual disturbance and hypersecretion of progesterone in women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Clinical Endocrinology (Oxford) 1995; 43: 291-296.
21. van Wyk JJ, Gunther DF, Ritzen EM et al. The use of adrenalectomy as a treatment for congenital adrenal hyperplasia. Journal of Clinical Endocrinology and Metabolism 1996; 81: 3180-3190.
22. Imperato-McGinley J, Binienda Z, Gedney J et al. Nipple differentiation in fetal male rats treated with an inhibitor of the enzyme 5 alpha-reductase: definition of a selective role for dihydrotestosterone. Endocrinology 1986; 118: 132-137.
23. Lo JC, Schwitzgebel VM, Tyrrell JB et al. Normal female infants born of mothers with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Journal of Clinical Endocrinology and Metabolism 1999; 84: 930-936.
24. Feldman S, Billaud L, Thalabard JC et al. Fertility in women with late-onset adrenal hyperplasia due to 21-hydroxylase deficiency. Journal of Clinical Endocrinology and Metabolism 1992; 74: 635-639.
25. Urban MD, Lee PA & Migeon CJ. Adult height and fertility in men with congenital virilizing adrenal hyperplasia. New England Journal of Medicine 1978; 299: 1392-1396.
26. Prader A, Zachmann M & Illig R. Fertility in adult males with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Acta Endocrinologica 1973; 177 (supplement): 57.
27. Willi U, Atares M, Prade A et al. Testicular adrenal-like tissue (TALT) in congenital adrenal hyperplasia: detection by ultrasonography. Pediatric Radiology 1991; 21: 284-287.
28. Avila NA, Shawker TS, Jones JV et al. Testicular adrenal rest tissue in congenital adrenal hyperplasia: serial sonographic and clinical findings. American Journal of Roentgenology 1999; 172: 1235-1238.
29. Vanzulli A, DelMaschio A, Paesano P et al. Testicular masses in association with adrenogenital syndrome: US findings. Radiology 1992; 183: 425-429.
30. Srikanth MS, West BR, Ishitani M et al. Benign testicular tumors in children with congenital adrenal hyperplasia. Journal of Pediatric Surgery 1992; 27: 639-641.
31. Walker BR, Skoog SJ, Winslow BH et al. Testis sparing surgery for steroid unresponsive testicular tumors of the adrenogenital syndrome. Journal of Urology 1997; 157: 1460-1463.
32. Berenbaum SA, Duck SC & Bryk K. Behavioral effects of prenatal versus postnatal androgen excess in children with 21-hydroxylase-deficient congenital adrenal hyperplasia. Journal of Clinical Endocrinology and Metabolism 2000; 85: 727-733.
33. Dittmann RW, Kappes ME & Kappes MH. Sexual behavior in adolescent and adult females with congenital adrenal hyperplasia. Psychoneuroendocrinology 1992; 17: 153-170.
34. Kuhnle U, Bullinger M & Schwarz HP. The quality of life in adult female patients with congenital adrenal hyperplasia: a comprehensive study of the impact of genital malformations and chronic disease on female patients life (see comments). European Journal of Pediatrics 1995; 154: 708-716.
35. Meyer-Bahlburg HF, Gruen RS, New MI et al. Gender change from female to male in classical congenital adrenal hyperplasia. Hormones and Behavior 1996; 30: 319-332.
36. Meyer-Bahlburg HF. Gender and sexuality in classic congenital adrenal hyperplasia. Endocrinology and Metabolism Clinics of North America 2001; 30: 155-171.
37. Berenbaum SA. Cognitive function in congenital adrenal hyperplasia. Endocrinology and Metabolism Clinics of North America 2001; 30: 173-172.
38. Jacobs AR, Edelheit PB, Coleman AE et al. Late-onset congenital adrenal hyperplasia: a treatable cause of anxiety. Biological Psychiatry 1999; 46: 856-859.
39. Al-Alwan I, Navarro O, Daneman D et al. Clinical utility of adrenal ultrasonography in the diagnosis of congenital adrenal hyperplasia. Journal of Pediatrics 1999; 135: 71-75.
40. Jaresch S, Kornely E, Kley HK et al. Adrenal incidentaloma and patients with homozygous or heterozygous congenital adrenal hyperplasia. Journal of Clinical Endocrinology and Metabolism 1992; 74: 685-689.
41. Ravichandran R, Lafferty F, McGinniss MJ et al. Congenital adrenal hyperplasia presenting as massive adrenal incidentalomas in the sixth decade of life: report of two patients with 21-hydroxylase deficiency. Journal of Clinical Endocrinology and Metabolism 1996; 81: 1776-1779.
42. Bauman A & Bauman CG. Virilizing adrenocortical carcinoma. Development in a patient with salt-losing congenital adrenal hyperplasia. JAMA 1982; 248: 3140-3141.
43. Lightner ES & Levine LS. The adrenal incidentaloma. A pediatric perspective (editorial; comment). American Journal of Diseases of Children 1993; 147: 1274-1276.
44. Charmandari E, Johnston A, Brook CG et al. Bioavailability of oral hydrocortisone in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Journal of Endocrinology 2001; 169: 65-70.
45. Kerrigan JR, Veldhuis JD, Leyo SA et al. Estimation of daily cortisol production and clearance rates in normal pubertal males by deconvolution analysis. Journal of Clinical Endocrinology and Metabolism 1993; 76: 1505-1510.
46. Charmandari E, Hindmarsh PC, Johnston A et al. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: alterations in cortisol pharmacokinetics at puberty. Journal of Clinical Endocrinology and Metabolism 2001; 86: 2701-2708.
47. Lo J & Grumbach M. Pregnancy outcomes in women with congenital virilizing adrenal hyperplasia. Endocrinology and Metabolism Clinics of North America 2001; 30: 207-229.
48. Seckl JR & Miller WL. How safe is long-term prenatal glucocorticoid treatment? (see comments) JAMA 1997; 277: 1077-1079.
49. New MI (editor). Prenatal Treatment of Congenital Adrenal Hyperplasia: the U.S. Experience. Philadelphia: Saunders, 2001.
50. Bode HH, Rivkees SA, Cowley DM et al. Home monitoring of 17 hydroxyprogesterone levels in congenital adrenal hyperplasia with filter paper blood samples (see comments). Journal of Pediatrics 1999; 134: 185-189.
51. Lamberts SW, Bruining HA & de Jong FH. Corticosteroid therapy in severe illness. New England Journal of Medicine 1997; 337: 1285-1292.
52. Zarkovic M, Ciric J, Stojanovic M et al. Optimizing the diagnostic criteria for standard (250-microg) and low dose (1-microg) adrenocorticotropin tests in the assessment of adrenal function. Journal of Clinical Endocrinology and Metabolism 1999; 84: 3170-3173.
53. Speiser PW, Agdere L, Ueshiba H et al. Aldosterone synthesis in salt-wasting congenital adrenal hyperplasia with complete absence of adrenal 21-hydroxylase. New England Journal of Medicine 1991; 324: 145-149.
54. Rosler A, Levine LS, Schneider B et al. The interrelationship of sodium balance, plasma renin activity and ACTH in congenital adrenal hyperplasia. Journal of Clinical Endocrinology and Metabolism 1977; 45: 500-512.
55. Reiner WG. Assignment of sex in neonates with ambiguous genitalia. Current Opinion in Pediatrics 1999; 11: 363-365.
56. Donahoe PK & Gustafson ML. Early one-stage surgical reconstruction of the extremely high vagina in patients with congenital adrenal hyperplasia. Journal of Pediatric Surgery 1994; 29: 352-358.
57. Schnitzer JJ & Donahoe PK. Surgical Treatment of Congenital Adrenal Hyperplasia. Philadelphia: Saunders, 2001.
58. Farkas A & Chertin B. Feminizing genitoplasty in patients with 46XX congenital adrenal hyperplasia. Journal of Pediatric Endocrinology and Metabolism 2001; 14: 713-722.
59. Creighton SM, Minto CL & Steele SJ. Objective cosmetic and anatomical outcomes at adolescence of feminising surgery for ambiguous genitalia done in childhood. Lancet 2001; 358: 124-125.
60. Powell DM, Newman KD & Randolph J. A proposed classification of vaginal anomalies and their surgical correction. Journal of Pediatric Surgery 1995; 30: 271-275;, discussion 275-276.
61. Pang S & Shook MK. Current status of neonatal screening for congenital adrenal hyperplasia (see comments). Current Opinion in Pediatrics 1997; 9: 419-423.
62. Cargill M, Altshuler D, Ireland J et al. Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nature Genetics 1999; 22: 231-238.
63. White PC, Vitek A, Dupont B et al. Characterization of frequent deletions causing steroid 21-hydroxylase deficiency. Proceedings of the National Academy of Sciences of the USA 1988; 85: 4436-4440.
64. Higashi Y, Tanae A, Inoue H et al. Aberrant splicing and missense mutations cause steroid 21-hydroxylase [P-450(C21)] deficiency in humans: possible gene conversion products. Proceedings of the National Academy of Sciences of the USA 1988; 85: 7486-7490.
65. White PC & Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocrology Reviews 2000; 21: 245-291.
66. Amor M, Parker KL, Globerman H et al. Mutation in the CYP21B gene (Ile-172 - Asn) causes steroid 21-hydroxylase deficiency. Proceedings of the National Academy of Sciences of the USA 1988; 85: 1600-1604.
67. Tusie-Luna MT, Traktman P & White PC. Determination of functional effects of mutations in the steroid 21-hydroxylase gene (CYP21) using recombinant vaccinia virus. Journal of Biological Chemistry 1990; 265: 20 916-20 922.
68. Wedell A, Thilen A, Ritzen EM et al. Mutational spectrum of the steroid 21-hydroxylase gene in Sweden: implications for genetic diagnosis and association with disease manifestation. Journal of Clinical Endocrinology and Metabolism 1994; 78: 1145-1152.
69. Jaaskelainen J, Levo A, Voutilainen R et al. Population-wide evaluation of disease manifestation in relation to molecular genotype in steroid 21-hydroxylase (CYP21) deficiency: good correlation in a well defined population. Journal of Clinical Endocrinology and Metabolism 1997; 82: 3293-3297.
70. Speiser PW, Dupont J, Zhu D et al. Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Journal of Clinical Investigation 1992; 90: 584-595.
71. Carlson AD, Obeid JS, Kanellopoulou N et al. Congenital adrenal hyperplasia: update on prenatal diagnosis and treatment. Journal of Steroid Biochemistry and Molecular Biology 1999; 69: 19-29.
72. Day DJ, Speiser PW, Schulze E et al. Identification of non-amplifying CYP21 genes when using PCR-based diagnosis of 21-hydroxylase deficiency in congenital adrenal hyperplasia (CAH) affected pedigrees. Human Molecular Genetics 1996; 5: 2039-2048.
73. Fitness J, Dixit N, Webster D et al. Genotyping of CYP21, linked chromosome 6p markers, and a sex-specific gene in neonatal screening for congenital adrenal hyperplasia. Journal of Clinical Endocrinology and Metabolism 1999; 84: 960-966.
74. Nordenstrom A, Thilen A, Hagenfeldt L et al. Genotyping is a valuable diagnostic complement to neonatal screening for congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency (see comments). Journal of Clinical Endocrinology and Metabolism 1999; 84: 1505-1509.
75. Therrell BL Jr, Berenbaum SA, Manter-Kapanke V et al. Results of screening 1.9 million Texas newborns for 21-hydroxylase-deficient congenital adrenal hyperplasia. Pediatrics 1998; 101: 583-590.
76. Tusie Luna MT & White PC. Gene conversions and unequal crossovers between CYP21 (steroid 21-hydroxylase gene) and CYP21P involve different mechanisms. Proceedings of the National Academy of Sciences of the USA 1995; 92: 10 796-10 800.
77. Witchel SF & Lee PA. Identification of heterozygotic carriers of 21-hydroxylase deficiency: sensitivity of ACTH stimulation tests. American Journal of Medical Genetics 1998; 76: 337-342.
78. Lejeune-Lenain C, Cantraine F, Dufrasnes M et al. An improved method for the detection of heterozygosity of congenital virilizing adrenal hyperplasia. Clinical Endocrinology (Oxford) 1980; 12: 525-535.
79. Milewicz A, Afelska A, Wasikowa R et al. Evaluation of 21-deoxycortisol as a marker for the detection of heterozygous carriers of 21-hydroxylase deficiency. Endokrynologia Polska 1993; 44: 187-193.
80. Knochenhauer ES, Cortet-Rudelli C, Cunningham RD et al. Carriers of 21-hydroxylase deficiency are not at increased risk for hyperandrogenism. Journal of Clinical Endocrinology and Metabolism 1997; 82: 479-485.
81. Pang SY, Wallace MA, Hofman L et al. Worldwide experience in newborn screening for classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Pediatrics 1988; 81: 866-874.